Janneke Meulenberg

Dr. Janneke Meulenberg is serving as Managing Director MeiraGTx Netherlands since November 2019. Dr. Meulenberg has over 25 years experience in different leadership roles in the biopharmaceutical industry. Prior to joining MeiraGTx, Dr. Meulenberg was Chief Operating Officer of Arthrogen B.V., a gene therapy company, and Chief Executive Officer of ViciniVax B.V., a cancer vaccine company. From 2008-2015, Dr. Meulenberg served as Chief Executive Officer of ORCA Therapeutics B.V. , a company developing oncolytic virotherapies. From 2000-2008, Dr. Meulenberg was member of the executive team of the gene therapy company Amsterdam Molecular Therapeutics (now UniQure), where she was responsible for product development. Before joining Amsterdam Molecular Therapeutics, Dr. Meulenberg was Project Manager at ID-Lelystad, a veterinary vaccine company. Dr. Meulenberg graduated cum laude from the University of Groningen, received a PhD in Biochemistry from the University of Amsterdam and holds an MBA from RSM Erasmus University.